Xenetic Biosciences Inc Financials
Xenetic Biosciences Inc (XBIO) reported $3.0M in revenue for fiscal year 2025, up 19.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Periodic equity funding rather than operating revenue is still the main engine keeping this development-stage business running.
FY2025 cash increased despite operating cash flow of-$2.3M , because financing inflows were$4.0M ; liquidity improved, but only through new capital. That matters because R&D spending at$3.1M still exceeded revenue of$3.0M , so the business is not yet paying for its own development work.
From FY2023 to FY2025, net loss narrowed from
The balance sheet is lightly encumbered: total liabilities were only
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Xenetic Biosciences Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Xenetic Biosciences Inc scores -27.99, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($8.4M) relative to total liabilities ($968K). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Xenetic Biosciences Inc passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
Xenetic Biosciences Inc reported a net loss of $2.7M while operations used $2.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Xenetic Biosciences Inc reported an operating loss of $2.8M against $148K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Xenetic Biosciences Inc generated $3.0M in revenue in fiscal year 2025. This represents an increase of 19.0% from the prior year.
Xenetic Biosciences Inc reported -$2.7M in net income in fiscal year 2025. This represents an increase of 32.3% from the prior year.
Xenetic Biosciences Inc earned -$1.58 per diluted share (EPS) in fiscal year 2025. This represents an increase of 38.5% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Xenetic Biosciences Inc held $7.9M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Xenetic Biosciences Inc's operating margin was -95.2% in fiscal year 2025, reflecting core business profitability. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Xenetic Biosciences Inc's net profit margin was -90.1% in fiscal year 2025, showing the share of revenue converted to profit. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Xenetic Biosciences Inc's ROE was -36.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 29.7 percentage points from the prior year.
Not reported for fiscal year 2025.
Capital Allocation
Xenetic Biosciences Inc invested $3.1M in research and development in fiscal year 2025. This represents a decrease of 6.8% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
XBIO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.3M | $3.0M+19.0% | $2.5M-1.6% | $2.5M+48.8% | $1.7M+47.1% | $1.2M+165.6% | $437K+2460.3% | $17K | $0-100.0% | $7.6M+152.8% | $3.0M | $0 | $0-100.0% | $1.0M+240.6% | $294K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0-100.0% | $45K |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $1.0M+302.0% | $249K |
| R&D Expenses | $2.7M | $3.1M-6.8% | $3.3M-5.9% | $3.5M-26.7% | $4.8M+50.8% | $3.2M+82.7% | $1.7M-64.6% | $4.9M+69.5% | $2.9M-29.0% | $4.1M-90.7% | $43.7M+1173.7% | $3.4M-45.7% | $6.3M+106.6% | $3.1M+57.5% | $1.9M |
| SG&A Expenses | $3.2M | $2.7M-19.6% | $3.4M-4.1% | $3.6M-2.5% | $3.7M-2.4% | $3.7M+10.1% | $3.4M-28.1% | $4.7M+7.7% | $4.4M-36.7% | $6.9M+3.7% | $6.7M+4.8% | $6.4M-3.2% | $6.6M+0.7% | $6.6M+84.0% | $3.6M |
| Operating Income | -$2.6M | -$2.8M+32.6% | -$4.2M+6.9% | -$4.5M+32.8% | -$6.7M-16.9% | -$5.7M+58.8% | -$13.9M-8.2% | -$12.9M-77.1% | -$7.3M-103.9% | -$3.6M+92.5% | -$47.4M-382.9% | -$9.8M+24.0% | -$12.9M-50.1% | -$8.6M-35.8% | -$6.3M |
| Interest Expense | N/A | $148K-40.8% | $250K-29.8% | $356K+112.8% | $167K+66.4% | $100K-20.4% | $126K+16.3% | $108K+21214.1% | $509-72.0% | $2K-99.8% | $730K+173.2% | $267K+5573.6% | $5K+644.6% | $632-98.8% | $52K |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0+100.0% | -$2.9M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | N/A |
| Net Income | -$2.5M | -$2.7M+32.3% | -$4.0M+4.2% | -$4.1M+36.9% | -$6.6M-16.1% | -$5.6M+48.2% | -$10.9M+14.7% | -$12.8M-75.0% | -$7.3M-103.1% | -$3.6M+93.4% | -$54.2M-333.4% | -$12.5M+12.6% | -$14.3M-66.8% | -$8.6M-9521.0% | -$89K |
| EPS (Diluted) | — | -$1.58+38.5% | -$2.57+5.2% | -$2.71+41.2% | -$4.61 | -$0.55 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
XBIO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $8.4M+21.2% | $6.9M-34.9% | $10.6M-28.0% | $14.7M-25.7% | $19.8M+50.3% | $13.2M-38.8% | $21.5M+49.3% | $14.4M-24.7% | $19.2M-8.6% | $21.0M+24.0% | $16.9M+3.6% | $16.3M-16.2% | $19.5M-23.3% | $25.4M |
| Current Assets | $8.0M+22.2% | $6.6M-31.3% | $9.6M-29.8% | $13.7M-27.1% | $18.7M+51.4% | $12.4M+11.5% | $11.1M+828.8% | $1.2M-79.7% | $5.9M-29.4% | $8.3M+99.0% | $4.2M+50.9% | $2.8M-47.9% | $5.3M-53.8% | $11.5M |
| Cash & Equivalents | $7.9M+27.9% | $6.2M-31.4% | $9.0M-31.4% | $13.1M-28.2% | $18.2M+58.3% | $11.5M+11.2% | $10.4M+1524.8% | $638K-88.6% | $5.6M+36.1% | $4.1M+3011.8% | $132K-94.7% | $2.5M-48.2% | $4.8M-56.5% | $11.1M |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $3.0M | $0 | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $9.2M+181.5% | $3.3M0.0% | $3.3M0.0% | $3.3M0.0% | $3.3M-5.2% | $3.5M-5.5% | $3.7M+2.0% | $3.6M |
| Total Liabilities | $968K+8.2% | $894K+10.5% | $810K-24.6% | $1.1M-24.5% | $1.4M+47.4% | $964K-77.8% | $4.3M-4.1% | $4.5M-7.1% | $4.9M+1.2% | $4.8M-53.4% | $10.3M+76.5% | $5.8M-14.8% | $6.8M+49.1% | $4.6M |
| Current Liabilities | $968K+8.2% | $894K+10.5% | $810K-24.6% | $1.1M-24.5% | $1.4M+51.7% | $937K-33.8% | $1.4M-11.5% | $1.6M-17.7% | $1.9M+4.2% | $1.9M-74.6% | $7.3M+172.0% | $2.7M-24.8% | $3.6M+156.5% | $1.4M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $213K |
| Total Equity | $7.4M+23.1% | $6.0M-38.7% | $9.8M-28.2% | $13.6M-25.8% | $18.4M+50.6% | $12.2M-29.0% | $17.2M+73.6% | $9.9M-30.7% | $14.3M-11.6% | $16.2M+144.7% | $6.6M-36.9% | $10.5M-16.9% | $12.6M-39.3% | $20.8M |
| Retained Earnings | -$199.9M-1.4% | -$197.2M-2.0% | -$193.2M-2.2% | -$189.1M-3.6% | -$182.5M-3.2% | -$176.9M-6.6% | -$166.0M-8.3% | -$153.2M-5.0% | -$145.9M-2.5% | -$142.3M-61.5% | -$88.1M-16.5% | -$75.6M-29.7% | -$58.3M-17.3% | -$49.7M |
Not reported in any period shown, so not listed: Inventory.
XBIO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.3M | -$2.3M+18.8% | -$2.8M+31.5% | -$4.1M+11.5% | -$4.6M+1.9% | -$4.7M-11.0% | -$4.3M+33.3% | -$6.4M+1.0% | -$6.5M-532.6% | $1.5M+117.0% | -$8.8M-65.8% | -$5.3M+58.2% | -$12.7M-109.6% | -$6.1M+3.4% | -$6.3M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $9K-44.8% | $17K+909.8% | $2K-97.1% | $58K-26.7% | $79K-39.6% | $130K |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$6.5M-535.3% | $1.5M+116.9% | -$8.8M-66.0% | -$5.3M+58.4% | -$12.7M-107.8% | -$6.1M+4.1% | -$6.4M |
| Investing Cash Flow | N/A | N/A | N/A | $0+100.0% | -$500K | $0 | $0-100.0% | $2K-91.1% | $23K+342.9% | -$9K+44.8% | -$17K | N/A | N/A | -$145K-56.2% | -$93K |
| Financing Cash Flow | N/A | $4.0M | $0 | N/A | $0-100.0% | $11.5M+111.1% | $5.4M-66.3% | $16.1M+989.7% | $1.5M | $0-100.0% | $12.7M | N/A | N/A | $2K+100.7% | -$303K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
XBIO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 100.0%+15.3pp | 84.7% |
| Operating Margin | -95.2% | -168.2% | -177.8% | -393.6% | -495.1% | -3189.8% | -75511.7% | N/A | -47.0% | -1581.0% | N/A | N/A | -861.4% | -2160.8% |
| Net Margin | -90.1% | -158.4% | -162.8% | -383.9% | -486.4% | -2493.1% | -74856.6% | N/A | -47.4% | -1806.9% | N/A | N/A | -857.9% | -30.4% |
| Return on Equity | -36.3%+29.7pp | -65.9%-23.7pp | -42.2%+5.8pp | -48.0%-17.3pp | -30.7%+58.5pp | -89.2%-15.0pp | -74.2%-0.6pp | -73.7%-48.5pp | -25.1%+310.1pp | -335.2%-146.0pp | -189.3%-52.8pp | -136.5%-68.5pp | -68.0%-67.6pp | -0.4% |
| Return on Assets | -32.0%+25.3pp | -57.4%-18.4pp | -39.0%+5.5pp | -44.5%-16.0pp | -28.5%+54.2pp | -82.7%-23.4pp | -59.3%-8.7pp | -50.6%-31.8pp | -18.8%+239.7pp | -258.4%-184.5pp | -74.0%+13.7pp | -87.7%-43.6pp | -44.1%-43.7pp | -0.4% |
| Current Ratio | 8.32+0.9x | 7.37-4.5x | 11.84-0.9x | 12.72-0.5x | 13.180.0x | 13.20+5.4x | 7.84+7.1x | 0.75-2.3x | 3.03-1.4x | 4.47+3.9x | 0.57-0.5x | 1.03-0.5x | 1.48-6.8x | 8.25 |
| Debt-to-Equity | 0.130.0x | 0.15+0.1x | 0.080.0x | 0.080.0x | 0.080.0x | 0.08-0.2x | 0.25-0.2x | 0.46+0.1x | 0.340.0x | 0.30-1.3x | 1.56+1.0x | 0.560.0x | 0.54+0.5x | 0.01 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 19.6% | -293.5% | N/A | N/A | -613.1% | -2177.1% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Xenetic Biosciences Inc Ranks
Frequently Asked Questions
What is Xenetic Biosciences Inc's annual revenue?
Xenetic Biosciences Inc (XBIO) reported $3.0M in total revenue for fiscal year 2025. This represents a 19.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Xenetic Biosciences Inc's revenue growing?
Xenetic Biosciences Inc (XBIO) revenue grew by 19.0% year-over-year, from $2.5M to $3.0M in fiscal year 2025.
Is Xenetic Biosciences Inc profitable?
No, Xenetic Biosciences Inc (XBIO) reported a net income of -$2.7M in fiscal year 2025, with a net profit margin of -90.1%.
What is Xenetic Biosciences Inc's operating margin?
Xenetic Biosciences Inc (XBIO) had an operating margin of -95.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Xenetic Biosciences Inc's net profit margin?
Xenetic Biosciences Inc (XBIO) had a net profit margin of -90.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Xenetic Biosciences Inc's return on equity (ROE)?
Xenetic Biosciences Inc (XBIO) has a return on equity of -36.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Xenetic Biosciences Inc's operating cash flow?
Xenetic Biosciences Inc (XBIO) recorded an outflow of $2.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Xenetic Biosciences Inc's total assets?
Xenetic Biosciences Inc (XBIO) had $8.4M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Xenetic Biosciences Inc spend on research and development?
Xenetic Biosciences Inc (XBIO) invested $3.1M in research and development during fiscal year 2025.
What is Xenetic Biosciences Inc's current ratio?
Xenetic Biosciences Inc (XBIO) had a current ratio of 8.32 as of fiscal year 2025, which is generally considered healthy.
What is Xenetic Biosciences Inc's debt-to-equity ratio?
Xenetic Biosciences Inc (XBIO) had a debt-to-equity ratio of 0.13 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Xenetic Biosciences Inc's return on assets (ROA)?
Xenetic Biosciences Inc (XBIO) had a return on assets of -32.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Xenetic Biosciences Inc's cash runway?
Based on fiscal year 2025 data, Xenetic Biosciences Inc (XBIO) had $7.9M in cash against an annual operating cash burn of $2.3M. This gives an estimated cash runway of approximately 41 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Xenetic Biosciences Inc's Altman Z-Score?
Xenetic Biosciences Inc (XBIO) has an Altman Z-Score of -27.99, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Xenetic Biosciences Inc's Piotroski F-Score?
Xenetic Biosciences Inc (XBIO) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Xenetic Biosciences Inc's earnings high quality?
Xenetic Biosciences Inc (XBIO) reported a net loss of $2.7M while operations used $2.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Xenetic Biosciences Inc cover its interest payments?
Xenetic Biosciences Inc (XBIO) reported an operating loss of $2.8M against $148K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Xenetic Biosciences Inc?
Xenetic Biosciences Inc (XBIO) scores 67 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.